U.S. Clinical Trials Market Size & Outlook, 2026-2033
Global Market
Related Markets
U.S. clinical trials market highlights
- The U.S. clinical trials market generated a revenue of USD 42,430.0 million in 2025 and is expected to reach USD 73,220.9 million by 2033.
- The U.S. market is expected to grow at a CAGR of 7.3% from 2026 to 2033.
- In terms of segment, phase iii was the largest revenue generating phase in 2025.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
Clinical trials market data book summary
| Market revenue in 2025 | USD 42,430.0 million |
| Market revenue in 2033 | USD 73,220.9 million |
| Growth rate | 7.3% (CAGR from 2026 to 2033) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase II, Phase III, Phase IV, Phase I |
| Key market players worldwide | Thermo Fisher Scientific Inc, Icon PLC, Charles River Laboratories International Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, PAREXEL, Wuxi AppTec Co Ltd, Labcorp Holdings Inc, Eli Lilly and Co, Novo Nordisk A/S ADR, Pfizer Inc, Caidya |
Other key industry trends
- In terms of revenue, U.S. accounted for 47.7% of the global clinical trials market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. clinical trials market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 664.7 million by 2033.
A high percentage of clinical trials across the U.S. is creating lucrative opportunities for the clinical trial market. Furthermore, high R&D spending on clinical trials has further fueled the local market. These grants aim to support the development of new medical products specifically for treating rare diseases.
The local presence of well-established contract research organizations in the U.S. boosts market growth. Leading companies include IQVIA; ICON plc; Parexel International Corporation; Syneos Health, Inc.; and Charles River Laboratory.
Market players are adopting strategies to remain competitive, including product launches to ease clinical trial processes, geographic expansion, the addition of new services to their portfolios, and collaborations.
No credit card required*
Publish Date: Oct 24, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Clinical Trials Market Scope
Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Icon PLC | View profile | 41,150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | www.iconplc.com |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| IQVIA Holdings Inc | View profile | 87,000 | 2400 Ellis Road, Durham, NC, United States, 27703 | www.iqvia.com |
| SGS AG | View profile | 103,193 | 1 Place des Alpes, P.O. Box 2152, Geneva, Switzerland, CH-1211 | www.sgs.com |
U.S. Clinical Trials Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Clinical Trials Market Outlook will help companies and investors design strategic landscapes.
Phase Iii was the largest segment with a revenue share of 57.0% in 2025.
Horizon Databook has segmented the U.S. clinical trials market based on phase ii, phase iii, phase iv, phase i covering the revenue growth of each sub-segment from 2021 to 2033.
A high percentage of clinical trials across the U.S. is creating lucrative opportunities for the clinical trial market. Furthermore, high R&D spending on clinical trials has further fueled the local market. These grants aim to support the development of new medical products specifically for treating rare diseases.
The local presence of well-established contract research organizations in the U.S. boosts market growth. Leading companies include IQVIA; ICON plc; Parexel International Corporation; Syneos Health, Inc.; and Charles River Laboratory.
Market players are adopting strategies to remain competitive, including product launches to ease clinical trial processes, geographic expansion, the addition of new services to their portfolios, and collaborations.
- U.S. Clinical Trials Market Phase Outlook (Revenue, USD Million , 2021-2033)
- Phase I
- Phase II
- Phase III
- Phase IV
- U.S. Clinical Trials Market Study Design Outlook (Revenue, USD Million , 2021-2033)
- Interventional Trials
- Observational Trials
- Expanded Access Trials
- U.S. Clinical Trials Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Autoimmune/Inflammation
- Pain management
- Oncology
- CNS conditions
- Diabetes
- Obesity
- Cardiovascular
- Others
- U.S. Clinical Trials Market Service Type Outlook (Revenue, USD Million , 2021-2033)
- Protocol Designing
- Site Identification
- Patient Recruitment
- Laboratory Services
- Analytical Testing Services
- Clinical Trial Data Management Services
- Others
- U.S. Clinical Trials Market Sponser Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical & Biopharmaceutical Companies
- Medical Device Companies
- Others
Reasons to subscribe to Clinical Trials Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Clinical Trials Market Outlook databook
- Our clientele includes a mix of Clinical Trials Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Clinical Trials Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Clinical Trials Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Clinical Trials Market, 2021-2033 (US$M)
U.S. clinical trials market statistics, by phase, 2021-2033 (US$M)
